Commercialization at UHN Analysis: $750K Raised
What is Commercialization at UHN?
Research commercialization hub at University Health Network
HQ Country
Toronto, Canada
Employees
11-50
Founded
1999
HQ State/Province
Ontario
HQ Full Address
Toronto, Ontario, Canada
Product Features & Capabilities
- Ex-vivo lung perfusion technology
- ADELA blood-based cancer diagnostics platform
- TREADWELL THERAPEUTICS cancer immunotherapy
- MEDLY THERAPEUTICS digital health platform for heart failure
- Porphyrin lipid nanoparticle drug delivery system
- Dry electrode technology for rehabilitation
How much Commercialization at UHN raised
Funding - $750K
Other Considerations
Acquired Trillium Therapeutics by Pfizer for $2.22B; Acquired BlueRock Therapeutics by Bayer for $1B; Secured $60M financing round for ADELA; Raised $91M Series B for TREADWELL; Formed 10+ start-ups since 2014; 4 years of exit valuations for UHN start-ups since 2018
